What happens when the world’s best HIV prevention tool meets the planet’s deadliest infectious disease? (opens original article in a new tab)

South Africa plans to use the HIV prevention shot lenacapavir (LEN) alongside TB treatments, requiring extra doses to maintain protection against HIV, with trials testing its effectiveness.

• LEN could cut new HIV infections to 65,000 per year by 2043 if 1-2 million people use it.
• TB medications like rifampicin reduce LEN levels, requiring extra doses for HIV protection.
• South Africa's plan includes extra LEN doses for TB patients, with trials underway to confirm effectiveness.